Search results
Results From The WOW.Com Content Network
CA27.29: breast cancer [10] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [11] CA-125: Mainly ovarian cancer, [12] but may also be elevated in for example endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer. [13] Calcitonin: medullary ...
This page was last edited on 4 November 2023, at 05:27 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. [25] The following is a list of human genes which encode carcinoembryonic antigen-related cell adhesion proteins: CEACAM1 , CEACAM3 , CEACAM4 , CEACAM5 , CEACAM6 , CEACAM7 , CEACAM8 , CEACAM16 , CEACAM18 , CEACAM19 , CEACAM20 , CEACAM21
Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary, [1] [2] [3] breast, colon, [4] lung, and pancreatic cancers.
Logical Observation Identifiers Names and Codes (LOINC) is a database and universal standard for identifying medical laboratory observations. First developed in 1994, it was created and is maintained by the Regenstrief Institute , a US nonprofit medical research organization.
CA 242 is a tumor marker for sialylated Lewis carbohydrates associated with adenocarcinomas and e-selectin-mediated metastatic risk. [ 1 ] [ 2 ] [ 3 ] It is commonly tested along with CEA, CA19-9 , and CA242 for detecting pancreatic cancer . [ 4 ]
Normetanephrine, also called normetadrenaline, [1] is a metabolite of norepinephrine created by action of catechol-O-methyl transferase on norepinephrine. It is excreted in the urine and found in certain tissues.
CA 27.29 (aka BR 27.29) and CA 15-3 measure different epitopes of the same protein antigen product of the MUC1 gene seen in breast cancer. CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.